Page 2463 - Williams Hematology ( PDFDrive )

2434 Index Index 2435

FLT3 inhibitors, for acute myelogenous Folate-binding proteins, of serum and milk, monoclonal antibodies, 1645–1646
leukemia, 1403 588 observation alone, 1644
Flt3 ligand (FL) Folate deficiency, 597–599 radioimmunotherapy, 1647
hematopoiesis and, 258f, 265 clinical features, 598 rituximab plus chemotherapy, 1645t,
in megakaryopoiesis, 1822 cobalamin deficiency and, 590–591, 590f 1646–1647, 1646f, 1646t
Fluconazole colon cancer and, 599 single agent chemotherapy, 1644,
as empiric therapy for infections, 385, 387t differential diagnosis, 598 1645t
prophylactic, 369, 389 etiology and pathogenesis, 583, 597–598 of limited stage I-II disease, 1644
Fludarabine phosphate (fludarabine), 322, HELLP syndrome and, 599 pragmatic approach to, 1649
324 laboratory features, 598 of transformed disease, 1648–1649
for acute myelogenous leukemia, 1396, neural tube defects and, 598 vaccine, 423
1402t nonhematologic effects, 598 transformed, 1648–1649, 1649f
adverse effects, 1534 in pregnancy, 120, 597–598 Follicular small-cleaved-cell lymphoma, 1594
autoimmune hemolytic anemia and, 831 therapy, course, and prognosis, 599 Follicular small noncleaved cell lymphoma,
for chronic lymphocytic leukemia, 1534, thrombocytopenia and, 1997 184t
1535, 1537 vascular disease and, 598–599 Folylpolyglutamates, 585–586
for follicular lymphoma, 1645t, 1647 Folate-dependent enzymes, 584–585 Folylpoly-γ-glutamyl synthase (FPGS),
for γ-heavy-chain disease, 1806 Folate hydrolase (glutamate carboxypeptidase 585–586
before hematopoietic cell transplantation, II), 586–587 Fondaparinux, 398–399
360 Folate supplementation, 584 for acute myocardial infarction, 2296
for μ-heavy-chain disease, 1810 for autoimmune hemolytic anemia, 839 clinical uses, 399
for mycosis fungoides, 1687 for paroxysmal nocturnal hemoglobinuria, for heparin-induced thrombocytopenia,
for pure red cell aplasia, 544 579 2030, 2031t
resistance to, 319t in pregnancy, 120, 584 mechanism of action, 398, 1922
structure, 323f for sideroblastic anemia, 920 pharmacology, 398
for Waldenström macroglobulinemia, for thalassemias, 753 for venous thromboembolism, 2274, 2274t
1793, 1795 Folic acid (pteroylglutamic acid), 584, 585f, Food/food additives, platelet function and,
Fluorescence in situ hybridization (FISH), 935. See also Folate 2079
175t, 176, 176f, 1711 Folic acid coenzymes, 584, 586t Forkhead box P3 (FOXP3), 1181, 1223
Fluorescent polymerase chain reaction Folinic acid, 584 Forkhead transcription factors (FKHD), 209
(F-PCR), 1716 Follicular dendritic cell tumors, 1110 Formaldehyde, 810
5-Fluorouracil Follicular hyperplasia, 1589f Formate starvation hypothesis, 590f, 591
megaloblastic anemia and, 606t Follicular lymphoma, 1641–1650 Formyl peptide receptor, 1014–1015
resistance to, 319t chromosomal abnormalities, 187, 224t, FORS blood group, 2332t
Fluoxetine, platelet effects, 2079 1495t, 1576, 1642–1643, 1642f Foscarnet, 386, 387t
Fluoxymesterone, for anemia of primary clinical features, 1641 Founder effects, 690
myelofibrosis, 1328 course and prognosis, 1649–1650, 1650f 4T score, 2029, 2029t
Flushing, skin, 6 definition and history, 1641 FOXN1, 1223
Fms-like tyrosine kinase-1 (Flt1), 2011 differential diagnosis, 1655, 1667, 1668 FOXO-1, 894
FN1, 1632 epidemiology, 1571, 1573, 1641 FOXP3 (forkhead box P3), 1181, 1223
FND regimen, for follicular lymphoma, 1645t extranodal, 1579 F-PCR (fluorescent polymerase chain
FNHTR (febrile nonhemolytic transfusion gene mutations, 170, 235–236t, 1495t, reaction), 1716
reaction), 2375 1594, 1643–1644 FPGS (folylpoly-γ-glutamyl synthase),
Foam cells, 1129, 1129f grades, 1594, 1594f, 1641, 1642f 585–586
Focal adhesion kinase (FAK), 266, 1841 laboratory features, 1495t, 1576f, 1594– Fractalkine, 62t, 69
FOG (friend of GATA), 271, 483–484 1595, 1594f, 1641–1643 Fragment X, of fibrinogen, 2310, 2310f
Folate, 583–588 prognostic factors, 1643–1644, 1643f Frameshift mutations, 146
blood levels, 588, 652t staging, 1643 Francisella tularensis, 1064f
chemistry, 584, 585f therapy Free light chains (FLCs), 1708, 1714,
daily requirements, 584 of advanced stage disease, 1644–1648 1741, 1742f, 1775, 1781. See also
excretion, 588 combination chemotherapy, 1645t Immunoglobulin (Ig) light chains
inborn errors of metabolism, 607–608 hematopoietic cell transplantation, Free radical hypothesis of aging, 130t, 131
metabolism, 584–586, 586f, 586t, 588 1648, 1648f Fresh-frozen plasma
in neutrophils, 935 idiotype vaccines, 1648 for afibrinogenemia, 2156
physiology, 586–587, 587f interferon-α, 1647–1648 for congenital thrombotic
sources, 584 maintenance rituximab, 1647 thrombocytopenic purpura, 2258

Kaushansky_index_p2393-2506.indd 2434 9/21/15 3:21 PM